Monitoring of low-molecular-weight heparins in cardiovascular disease

American Journal of Cardiology

Volumn 82, Issue 5 B, 1998, Pages

  Abbate, Rosanna ^a   Gori, Anna Maria ^a   Farsi, Alessandro ^a   Attanasio, Monica ^a   Pepe, Guglielmina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; REVIPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; PATIENT MONITORING; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 0006104640     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00111-8     Document Type: Conference Paper

References (25)

1. Mardiguian J, Trillou M. Studies on heparin fragments: relationship between the degree of polymerization and the factor Xa and thrombin inhibiting activity. Thromb Haemost 1983;50:72-79.
2. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984;218:725-732.
3. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
4. Barrocliffe TW. Low molecular weight heparin(s). Br J Haematol 1995;90: 1-7.
5. Hoppensteadt D, Jeske W, Fareed J. Laboratory monitoring of new anticoagulant and antithrombotic drugs. In: Pifarré R, ed. New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus, 1997;521-537.
6. Vukovic T, Proidl S, Teufelsbauer H, Kautzky A, Erlacher L, Luger A, Weissel M. Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin. Thromb Res 1992;66:735-743.
7. Harenberg J, Giese Ch, Dempfle CE, Stehle G, Heene DL. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers. Thromb Haemost 1989;61:357-362.
8. Bara L, Mardinguian J, Samama M. In vitro effect on HEPtest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990;57:585-592.
9. Yin E, Stockhausen DC. Appraisal of clot-based and amidolytic anti-Xa methods for the monitoring of heparin and its derivatives. Semin Thromb Haemost 1985; 11:243-244.
10. Bara L, Combe-Tamzali S, Conard J, Horellou MH, Samama M. Laboratory monitoring of a low molecular weight heparin (Enoxaparin) with a new clotting test (HEPtest) Haemostasis 1987;17:127-133.
11. Agnelli G, Iorio A, Renga C, Boschetti E, Nenci GG, Ofosu FA, Hirsh J. Prolonged antithrombin activity of low molecular weight heparin: clinical implications for the treatment of thromboembolic diseases. Circulation 1995;92:2819-2824.
12. Lindhal AK. Tissue factor pathway inhibitor: a potent inhibitor of in vitro coagulation and in vivo thrombus formation. Curr Opin Lipidol 1994;5:434-439.
13. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-7546.
14. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins: a developmental perspective. Exp Opin Invest Drugs 1997;6: 706-733.
15. Kristensen HI, Ostergaard PB, Nordfang O, Abilgaard U, Lindhal AK. Effect of tissue factor pathway inhibitor (TFPI) in the HEPtest assay and in an amidolytic anti factor Xa assay for LMW heparin. Thromb Haemost 1992;68:310-314.
16. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low molecular weight heparin Fragmin in the treatment of deep venous thrombosis. Thromb Haemost 1994;71: 698-702.
17. Faxon DP, Spiro TE, Minor S, Coté G, Douglas J, Gottlieb R, Califf R, Dorosti K, Topol E, Gordon JB, Ohmen M and the ERA investigators. Low molecular weight heparin in prevention of restenosis after angioplasty: results of enoxaparin restenosis (ERA) trial. Circulation 1994;90:908-916.
18. Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-318.
19. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, Holder D, Finnie K, Marquis JF, Naqvi S, Cohen E for the EMPAR collaborators. Fish oils and low molecular weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty: the EMPAR study. Circulation 1996;94: 1553-1560.
20. Karsch KR, Preisack MB, Baildon R, Eschenfelder V, Foley D, Garcia EJ, Kaltenbach M, Meisner C, Selbmann HK, Serruys PW, Shiu MF, Sujatta M, Bonan R and the REDUCE trial group. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: results of a randomized, double-bind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). J Am Coll Cardiol 1996;28:1437-1443.
21. Fragmin during instability in coronary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
22. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Promell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premmereur J, Bigonzi F for the efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group (ESSENCE). A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. New Engl J Med 1997;337:447-453.
23. Klein W, Buchwald A, Hillis SE, Monrad SM, Sanz G, Turpie GG, Van der Meer J, Olaisson E, Undeland S, Ludwig K for the FRIC Investigators. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96: 61-68.
24. Boneau B. Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994;72:330-334.
25. Cadroy Y, Pourrat J, Baladren MF, Saivin S, Houin G, Montastrue JL, Vernier I, Boneau B. Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thromb Res 1991;63:385-390.